DNQX

• Description:

  DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) [1].

• Product Name Alternative:

  FG 9041

• UNSPSC:

  12352005

• Hazard Statement:

  H228, H301+H311+H331, H315, H319

• Target:

  IGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/DNQX.html

• Purity:

  99.26

• Solubility:

  DMSO : ≥ 35 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1C(NC2=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C2N1)=O

• Molecular Formula:

  C8H4N4O6

• Molecular Weight:

  252.14

• Precautions:

  H228, H301+H311+H331, H315, H319

• References & Citations:

  [1]Honoré T, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 1988;241 (4866) :701-703.|[2]Lee SH, et al. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol. 2010;103 (4) :1728-1734.|[3]Sharp JW, et al. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687 (1-2) :114-124.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  AMPA Receptor; Kainate Receptor

• CAS Number:

  2379-57-9